RESULTS OF THE AUTOLOGOUS MESENCHYMAL STEM CELL TRANSPLANTATION IN PATIENTS WITH TYPE 1DIABETES MELLITUS
Loading...
Date
2020
Authors
Ulyanova, O.
Baigenzhin, A.
Askarov, M.
Kozina, L.
Karibekov, T.
Taubaldieva, Zh.
Serebrennikova, D.
Boltanova, A.
Journal Title
Journal ISSN
Volume Title
Publisher
International conference "MODERN PERSPECTIVES FOR BIOMEDICAL SCIENCES: FROM BENCH TO BEDSIDE”; National Laboratory Astana
Abstract
Introduction: Type 1diabetes mellitus (T1DM) remains one of the main public healthcare problems
worldwide with a tendency to steady growth. T1DM leads to kidney failure, blindness, heart attacks and
strokes, which account for high rates of morbidity and mortality among patients with T1DM. A replacement
of beta cells is the goal of therapy for T1DM. Recent clinical studies have shown a promising stem
cell role in the treatment of T1DM. We evaluated the therapeutic effect of autologous mesenchymal stem
cell transplantation (AMSCT) on carbohydrate metabolism markers in T1DM patients.
Methods: We examined 7 patients (5 male, 2female, aged 20-42) with T1DM, who underwent AMSCT
(cells were obtained from the patients’ iliac crest and cultivated for 3-4 weeks) by intravenous infusion.
The quantity of autologous mesenchymal stem cells infused was from 95 to 97 × 106. We analyzed the
daily insulin dosages, glycated hemoglobin (HbA1c), glutamic acid decarboxylase (GAD) antibody and
Langerhans antibody levels in patients before, 1, 2and 3 months after the AMSCT procedure.
Results: In patients with T1DM, AMSCT led to decrease in daily insulin dosage levels from 58,81±
13,71Units to 47,5± 12,7 Units (p=0,04) with trend to increase leptin levels and decrease HbA1c levels,
from 7,73 + 3.5 ng/ml to 16,9 ± 8,31ng/ml (p= 0,046) and 9,59±1,73% to 8,65±0,93 % (p = 0,092) after
1month, respectively. GAD antibody and Langerhans antibody levels didn’t change significantly after AMSCT:
from 10,79 + 4,52IU/ml to 12,33 ± 3,81IU/ml (p> 0,05) and 14,12+4,26 IU/mL to 18,17+9,03 IU/mL
(р=0,485) after 3 months, respectively.
Conclusions: The AMSCT led to decrease of the daily insulin dosage levels with increase of the leptin
levels after 1month without increasing of the GAD and Langerhans antibody levels within 3 months in
patients with T1DM.
Description
Keywords
Autologous bone-marrow derived stem cells, Type1diabetes mellitus, Glycated hemoglobin, Research Subject Categories::MEDICINE